Esophagectomy in Patients With Liver Cirrhosis
1 other identifier
observational
170
1 country
1
Brief Summary
Retrospective and confounder adjusted comparison of perioperative and longterm outcomes of patients requiring an esophagectomy for esophageal cancer with and without concomitant liver cirrhosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
March 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 18, 2021
CompletedFirst Posted
Study publicly available on registry
March 22, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2021
CompletedMay 23, 2023
May 1, 2023
6 months
March 18, 2021
May 21, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Long-term survival
5 years
Secondary Outcomes (8)
Major complication
90 days postoperatively
Anastomotic leakage rate
90 days postoperatively
Sepsis rate
90 days postoperatively
Renal failure rate
90 days postoperatively
Hepatic failure rate
90 days postoperatively
- +3 more secondary outcomes
Study Arms (2)
LC (liver cirrhotic patients)
Patients with concomitant liver cirrhosis
Non-LC (non liver cirrhotic patients)
Patients without concomitant liver cirrhosis
Interventions
retrospective comparison of esophagectomy for esophageal cancer in patients with or without concomitant liver cirrhosis
Eligibility Criteria
retrospective analysis of a prospective maintained database of EC patients operated at the institution between 2012 to 2016
You may qualify if:
- age ≥ 18 years
- primary esophageal cancer with indication for curative treatment
- follow up period ≥ 5 years
- LC cohort: pre- or intraoperative histological proof of liver cirrhosis
You may not qualify if:
- recurrent esophageal cancer
- missing indication for curative treatment of esophageal cancer
- esophagectomy for benign esophageal lesions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Hamburg Medical Institutions
Hamburg, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Reeh, MD
1Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 18, 2021
First Posted
March 22, 2021
Study Start
October 1, 2020
Primary Completion
March 18, 2021
Study Completion
April 10, 2021
Last Updated
May 23, 2023
Record last verified: 2023-05